Navigation Links
Japan Bioinformatics Announces Release of a Case Study on Detecting SNPs and Short INDELs
Date:4/25/2013

Tokyo, Japan (PRWEB) April 25, 2013

TOKYO, Japan – April 25, 2013 – Japan Bioinformatics, today announced the release of their case study: Simbiot® ‘How To’: SNP and INDEL Detection.

The case study describes several approaches for performing the identification of mutations, including single nucleotide polymorphisms (SNPs), short insertions and deletions (INDELs), as well as other genomic variations such as intermediate and long INDELs, tandem duplications, substitutions and inversions. There is a comparison of different mutation discovery algorithms, an outline of the issues of mutation analysis specific to haploid organisms, and an overview of the process of mutation detection using RNASeq data.

The case study includes four steps for detecting SNPs and short INDELs using NGS data, with a comparison of two of the most popular tools, and a look at some of the complexities in analyzing RNASeq data.

“There is significant confusion in the market regarding how to best analyze and compare NGS data. We are in constant discussions with industry and academic professionals who are looking for solutions to this problem. Simbiot® has helped many customers overcome these data inconsistencies, and be able to offer a truly differentiated, but sound platform for those analyzing genomic data,” said Boris Umylny, President of Japan Bioinformatics.

For the complete results of the analysis of sequence data, download the white paper here

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Patheon to Feature its Complex Formulation Technologies Expertise at the Upcoming CPhI – P-MEC –ICSE – BioPh – Pharmatec – Medtec Japan – Conference
2. LamdaGen Corporation Announces Japan Patent Issuance for Enzymatic Diagnostic Assays on Plasmonic Nano-Sensors
3. XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
4. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
5. Japan Bioinformatics Announces the Release of their Simbiot® Time Course Analysis ‘How-To’ Guide
6. WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan
7. Elsevier and Kanazawa University in Japan Collaborate to Map Universitys Research Performance
8. Japanese Universities Offered Access to SPIE Digital Library in Collaboration with JUSTICE
9. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
10. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
11. First Baby With Artificial Heart in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s ... reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in Calgary ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Cup may be two years away, but soccer aficionados ... for global competition when the National Institute of Standards ... second-ever international nanosoccer contest next summer. , Nanosoccerthe Lilliputian ... challenge one another on fields no bigger than a ...
... November 14, 2008 at 9:00 a.m. Eastern ... ... Inc. (Nasdaq: ALSE ) today reports operational and,financial results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged by the ...
... Spherix Incorporated,(Nasdaq: SPEX ) reported a net ... 2008 of $1.7 million ($0.12 per share) and $4.8 ... related to the commercialization of Naturlose as a treatment ... nine month period ended,September 30, 2008, compared to approximately ...
Cached Biology Technology:Let the games begin! Nanosoccer at 2009 RoboCup in Austria 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Spherix Reports 3rd Quarter Earnings 2
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... are leading the largest ever international research project into ... The research will aim to provide new insights into ... kills up to 40,000 women and almost one million ... study, DNA collected from thousands of pregnant women, including ...
... about to be published in EPJ E, French physicists from ... of a thin layer of cells in contact with an ... elastic films. Understanding the mechanism by which a thin layer ... structural integrity, bears great significance because the human tissue, or ...
... TAMPA, Fla. (May 16, 2012) Chlorothalonil, ... on food crops and golf courses, was lethal to ... study, University of South Florida researchers said Wednesday. ... study published in the journal Ecology Letters , ...
Cached Biology News:Nottingham researchers lead world's largest study into pre-eclampsia 2USF study: Common fungicide wreaks havoc on freshwater ecosystems 2